MPO and myeloid sarcoma: In line with deleterious effects of MPO-generated 2-ClHDA [15], the MPO inhibitor N-acetyl lysyltyrosylcysteine amide ameliorates brain damage in a murine model of stroke [30] and counteracts BBB damage in a murine model of MS [31].